{"disease":{"id":"pancreatic-head-cancer","name":"pancreatic head cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04075305","title":"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT05697198","title":"PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine","phase":"","overall_status":"COMPLETED","enrollment_count":1429,"lead_sponsor_name":"Labcorp Corporation of America Holdings, Inc","has_results":false},{"nct_id":"NCT02292914","title":"Prospective Analysis of Robot-Assisted Surgery","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1120,"lead_sponsor_name":"Instituto do Cancer do Estado de São Paulo","has_results":false},{"nct_id":"NCT05179824","title":"Tempus Priority Study: A Pan-tumor Observational Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Tempus AI","has_results":false},{"nct_id":"NCT06885424","title":"A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT03207867","title":"A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05708950","title":"A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":314,"lead_sponsor_name":"Kineta Inc.","has_results":false},{"nct_id":"NCT04544046","title":"Supportive Oncology Care At Home RCT","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06372886","title":"Clinical Outcomes of Preservation Versus Resection of Portal/Superior Mesenteric Vein During Pancreaticoduodenectomy in Pancreatic Cancer Patients Who Respond to Neoadjuvant Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":264,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03752398","title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT07155525","title":"Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":194,"lead_sponsor_name":"Minia University","has_results":false},{"nct_id":"NCT01351103","title":"A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":185,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03997968","title":"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Cyteir Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT03329950","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT04682431","title":"A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT03983954","title":"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"NeoTX Therapeutics Ltd.","has_results":false},{"nct_id":"NCT05651022","title":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Indaptus Therapeutics, Inc","has_results":false},{"nct_id":"NCT03454451","title":"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Corvus Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06710756","title":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"Perspective Therapeutics","has_results":false},{"nct_id":"NCT04801095","title":"A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Wellmarker Bio","has_results":false},{"nct_id":"NCT07532759","title":"Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive Jaundice","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Xu'an Wang","has_results":false},{"nct_id":"NCT06091930","title":"A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":97,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT07232810","title":"Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Minia University","has_results":false},{"nct_id":"NCT04068896","title":"Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"NGM Biopharmaceuticals, Inc","has_results":true},{"nct_id":"NCT04823832","title":"Endoscopic Versus Percutaneous Biliary Drainage for Resectable Pancreatic Head Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Hani Alhadad","has_results":false},{"nct_id":"NCT03849469","title":"A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT06910657","title":"IDOV-Immune for Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"ViroMissile, Inc.","has_results":false},{"nct_id":"NCT05461430","title":"Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Travera Inc","has_results":false},{"nct_id":"NCT02897375","title":"Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05259696","title":"Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Palleon Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05070247","title":"A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":61,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04383210","title":"Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":54,"lead_sponsor_name":"Elevation Oncology","has_results":true},{"nct_id":"NCT05872867","title":"Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Wellmarker Bio","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT04666688","title":"LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"PureTech","has_results":false},{"nct_id":"NCT04045496","title":"A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Jacobio Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT05169437","title":"Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Tempus AI","has_results":true},{"nct_id":"NCT05605522","title":"A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"3B Pharmaceuticals GmbH","has_results":false},{"nct_id":"NCT04121286","title":"A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Allist Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03525392","title":"Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Ipsen","has_results":true},{"nct_id":"NCT05395052","title":"FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT04644315","title":"A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04566393","title":"Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT04100694","title":"Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Merus B.V.","has_results":false}],"total":45},"guidelines":[],"source":"Drug Landscape verified database"}